Remote Incentives for Smoking Cessation Among AN Pregnant Women
Primary Purpose
Smoking, Smoking Cessation
Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Smartphone-based Financial Incentives
Best Practices
Sponsored by

About this trial
This is an interventional treatment trial for Smoking
Eligibility Criteria
Inclusion Criteria:
- ≥ 18 years of age
- report being smokers at the time they learned of the current pregnancy
- report smoking in the 7 days prior to completing their preliminary eligibility screening
- < 25 weeks pregnant
- speak English
- own a smartphone (Android or iOS)
- self-report as an Alaska Native
- current smoker as verified by saliva cotinine test
Exclusion Criteria:
- current or prior mental or medical condition that may interfere with study participation
- smoke marijuana more than once each week and not willing to quit (marijuana smoking can inflate breath CO)
- exposed to unavoidable occupational sources of CO (e.g., car mechanic)
- report currently receiving opioid maintenance therapy (e.g., methadone, buprenorphine)
Sites / Locations
- Alaska Native Tribal Health Consortium
- University of VermontRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Best Practices + Incentives group
Best Practices
Arm Description
Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
Participants assigned to this condition will receive the best practices treatment alone.
Outcomes
Primary Outcome Measures
Late Pregnancy Quit Rate
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Secondary Outcome Measures
Early Pregnancy Quit Rate
Point prevalence smoking abstinence (defined as a cotinine negative saliva test AND self-reported no smoking in the past seven days)
4-Week Postpartum Quit Rate
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
8-Week Postpartum Quit Rate
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
12-Week Postpartum Quit Rate
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
24-Week Postpartum Quit Rate
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Longest Duration of Abstinence (LDA)
Consecutive days of no smoking using biochemical verification (cotinine-negative saliva at the formal assessments) plus self-report (cigarettes per day from enrollment to 24 weeks postpartum reported during timeline follow-back conducted over the phone)
Full Information
NCT ID
NCT05019170
First Posted
August 9, 2021
Last Updated
June 9, 2022
Sponsor
University of Vermont
Collaborators
Alaska Native Tribal Health Consortium, Mayo Clinic
1. Study Identification
Unique Protocol Identification Number
NCT05019170
Brief Title
Remote Incentives for Smoking Cessation Among AN Pregnant Women
Official Title
Smartphone-based Financial Incentives to Promote Smoking Cessation Among Alaska Native Pregnant Women
Study Type
Interventional
2. Study Status
Record Verification Date
June 2022
Overall Recruitment Status
Recruiting
Study Start Date
December 15, 2021 (Actual)
Primary Completion Date
August 31, 2023 (Anticipated)
Study Completion Date
August 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Vermont
Collaborators
Alaska Native Tribal Health Consortium, Mayo Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Cigarette smoking during pregnancy increases risk for catastrophic pregnancy complications, growth retardation, other adverse infant health problems, and later-in-life chronic conditions. One group that is particularly at risk for these complications are Alaska Native (AN) women. Prevalence of smoking during pregnancy is disproportionally high among AN women compared to US pregnant women overall (i.e., ~36% and ~13%, respectively) and few smoking-cessation interventions have been evaluated among this population. A substantive barrier to offering evidence-based interventions to AN women is the geographic remoteness of Alaska. The most effective intervention for promoting smoking cessation during pregnancy is financial incentives in which participants earn incentives (e.g., cash) contingent on objective evidence of smoking abstinence. This intervention has been adapted to be delivered entirely through a smartphone meaning that the geographic remoteness of Alaska will not be a barrier with this intervention. Participants submit videos of themselves completing breath and saliva tests, and incentives are then delivered through the application if the tests indicate smoking abstinence. Through a collaboration between the University of Vermont and the Alaska Native Tribal Health Consortium, the goal of this study is to examine the preliminary feasibility and efficacy of this smartphone-based incentives intervention among AN women. Pregnant AN women will be recruited through ads posted on social media. Eligible participants who complete the informed consent process will be randomized to either: Best Practices or Best Practices + Incentives. In the Best Practices condition, participants will receive three brief educational sessions and a referral to the Alaska state quitline. In the Best Practices + Incentives condition, participants will receive the same education sessions and quitline referral, plus financial incentives contingent on the smartphone-based testing of breath and saliva specimens indicating abstinence from recent smoking. Outcomes will include point prevalence smoking abstinence at assessments conducted in late pregnancy and 4-, 8-, 12-, and 24-weeks postpartum, continuous abstinence during antepartum and postpartum, and perceived barriers and facilitators of treatment engagement. Overall, this project has the potential to address disparities in access to efficacious, evidence-based smoking cessation treatments among AN pregnant women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking, Smoking Cessation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
The investigators are proposing a two-condition, parallel groups, randomized controlled pilot study of a smartphone-based financial incentives intervention for AN pregnant smokers. The experimental group will receive financial incentives (money loaded onto a debit card) contingent on the remote submission of breath carbon monoxide and saliva cotinine tests indicating smoking abstinence in addition to best practices for promoting smoking cessation (Best Practices + Incentives). The control group will receive best practices alone (Best Practices). The use of a best practices group reflects a real-world comparison condition in that all women will receive the treatment that practitioners in the community are instructed to provide (the 5As + quitline referral) thereby enhancing the ecological validity of the study. Additionally, the investigators will minimize between-subject variability in the participant's exposure to these practices by implementing these treatment components themselves.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Best Practices + Incentives group
Arm Type
Experimental
Arm Description
Participants assigned to this condition will receive the best practices treatment plus the financial incentives intervention.
Arm Title
Best Practices
Arm Type
Active Comparator
Arm Description
Participants assigned to this condition will receive the best practices treatment alone.
Intervention Type
Behavioral
Intervention Name(s)
Smartphone-based Financial Incentives
Other Intervention Name(s)
Contingency Management
Intervention Description
Financial Incentives - Beginning on the quit date and extending for one week, participants will be required to submit twice daily CO samples. All samples < 6 ppm will be considered negative and those > 6 ppm will be considered positive. Participants will earn incentives for breath tests indicating smoking abstinence, and incentive values will increase with each consecutive negative sample. Following the initial quit week, the schedule of monitoring will be reduced, and incentives will be contingent on submitting a negative saliva cotinine test.
Intervention Type
Behavioral
Intervention Name(s)
Best Practices
Intervention Description
Best Practices- The 2008 Clinical Practice Guidelines for smoking cessation recommends that pregnant smokers be provided with the 5As. Research staff will implement the 5As at assessments that take place during pregnancy.
Primary Outcome Measure Information:
Title
Late Pregnancy Quit Rate
Description
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Time Frame
28 weeks gestation through date of delivery
Secondary Outcome Measure Information:
Title
Early Pregnancy Quit Rate
Description
Point prevalence smoking abstinence (defined as a cotinine negative saliva test AND self-reported no smoking in the past seven days)
Time Frame
One month after participant's enrollment date
Title
4-Week Postpartum Quit Rate
Description
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Time Frame
4 weeks following the date that participants deliver their infant
Title
8-Week Postpartum Quit Rate
Description
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Time Frame
8 weeks following the date that participants deliver their infant
Title
12-Week Postpartum Quit Rate
Description
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Time Frame
12 weeks following the date that participants deliver their infant
Title
24-Week Postpartum Quit Rate
Description
Point prevalence smoking abstinence (defined as a cotinine-negative saliva test AND self-reported no smoking in the past seven days)
Time Frame
24 weeks following the date that participants deliver their infant
Title
Longest Duration of Abstinence (LDA)
Description
Consecutive days of no smoking using biochemical verification (cotinine-negative saliva at the formal assessments) plus self-report (cigarettes per day from enrollment to 24 weeks postpartum reported during timeline follow-back conducted over the phone)
Time Frame
LDA will be measured from participant's date of enrollment in the study to 24-weeks postpartum
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
≥ 18 years of age
report being smokers at the time they learned of the current pregnancy
report smoking in the 7 days prior to completing their preliminary eligibility screening
< 25 weeks pregnant
speak English
own a smartphone (Android or iOS)
self-report as an Alaska Native
current smoker as verified by saliva cotinine test
Exclusion Criteria:
current or prior mental or medical condition that may interfere with study participation
smoke marijuana more than once each week and not willing to quit (marijuana smoking can inflate breath CO)
exposed to unavoidable occupational sources of CO (e.g., car mechanic)
report currently receiving opioid maintenance therapy (e.g., methadone, buprenorphine)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Tyler G Erath, PhD
Phone
336-688-7599
Email
tyler.erath@uvm.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Diann Gaalema, PhD
Phone
802-656-9874
Email
Diann.Gaalema@med.uvm.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Diann Gaalema, PhD
Organizational Affiliation
University of Vermont
Official's Role
Principal Investigator
Facility Information:
Facility Name
Alaska Native Tribal Health Consortium
City
Anchorage
State/Province
Alaska
ZIP/Postal Code
99508
Country
United States
Individual Site Status
Active, not recruiting
Facility Name
University of Vermont
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tyler G Erath, PhD
Phone
336-688-7599
Email
tyler.erath@uvm.edu
First Name & Middle Initial & Last Name & Degree
Diann Gaalema, PhD
Phone
802-656-9874
Email
Diann.Gaalema@med.uvm.edu
First Name & Middle Initial & Last Name & Degree
Diann Gaalema, PhD
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32652133
Citation
Kurti AN, Tang K, Bolivar HA, Evemy C, Medina N, Skelly J, Nighbor T, Higgins ST. Smartphone-based financial incentives to promote smoking cessation during pregnancy: A pilot study. Prev Med. 2020 Nov;140:106201. doi: 10.1016/j.ypmed.2020.106201. Epub 2020 Jul 9.
Results Reference
background
Learn more about this trial
Remote Incentives for Smoking Cessation Among AN Pregnant Women
We'll reach out to this number within 24 hrs